KPTI · Karyopharm Therapeutics Inc
United States · RS rating 1 · As of 2026-10-14
| Price | 0.31 USD |
|---|---|
| 1-day change | -26.3% |
| RS rating (overall / 1M / 3M / 12M) | 1 / 1 / 1 / 2 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 20 / 4 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -49.5% |
| Sales growth Q/Q | -22.6% |
| Distance from 52-week high | +97.0% |
| Market cap (USD) | $197.3M |